Mucin 16–Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes Eligible patients had metastatic PDAC and ...
After FDA rejects Saol's ultrarare disease prospect, advocacy groups urge patients to press Congress
After previously delaying its decision date, the FDA has outright rejected Saol Therapeutics’ investigational treatment for an ultrarare pediatric mitochondrial disease. The CNS-focused biotech is ...
Survivors of high-risk neuroblastoma treated with modern therapies demonstrated a substantial burden of late effects, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback